Literature DB >> 19328911

Current indications for hand and face allotransplantation.

S T Hollenbeck1, D Erdmann, L S Levin.   

Abstract

There is growing excitement centered on the possibilities of composite tissue allotransplantation (CTA) in many medical centers around the United States. As CTA programs begin to form, criteria to guide patient selection for these highly complex procedures is warranted. At this time the contraindications for CTA are more easily defined than the indications. What is clear is that a thorough multidisciplinary evaluation of each individual patient will be needed to determine the global impact and complexity of the defect. The role of the surgeon is to identify the feasibility of the CTA reconstruction and balance this with a complete knowledge of conventional reconstructive techniques. Conventional treatments may be used in place of CTA or as salvage for CTA failure.

Entities:  

Mesh:

Year:  2009        PMID: 19328911     DOI: 10.1016/j.transproceed.2009.01.065

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Evolution and trends in reconstructive facial surgery: an update.

Authors:  Oladimeji A Akadiri
Journal:  J Maxillofac Oral Surg       Date:  2012-05-13

2.  Upper extremity transplantation: current concepts and challenges in an emerging field.

Authors:  River M Elliott; Scott M Tintle; L Scott Levin
Journal:  Curr Rev Musculoskelet Med       Date:  2014-03

Review 3.  Building a Hand and Upper Extremity Transplantation Program: Lessons Learned From the First 20 Years of Vascularized Composite Allotransplantation.

Authors:  Shaun D Mendenhall; Stav Brown; Oded Ben-Amotz; Michael W Neumeister; L Scott Levin
Journal:  Hand (N Y)       Date:  2018-07-31

Review 4.  A review of utilities and costs of treating upper extremity amputations with vascularized composite allotransplantation versus myoelectric prostheses in Canada.

Authors:  J I Efanov; B Tchiloemba; A Izadpanah; P G Harris; M A Danino
Journal:  JPRAS Open       Date:  2022-03-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.